Patient Profiles

SYMBICORT can benefit a variety of patient types

Learn about the types of patients who have benefited from SYMBICORT therapy. Choose a patient below to get started.

Newly Diagnosed Gailene, Age 40 History First-time patient complaining of wheezing in the morning several times a week Experiencing shortness of breath that interferes with daily activities Treatment Prescribed albuterol and is currently taking 3 to 4 times a day Symptoms still persist and are indicative of moderate persistent asthma Watch	Morning Albuterol User Guy, Age 43 History Initially diagnosed with mild persistent asthma Symptoms have recently become more severe, and asthma is now moderate persistent Treatment Currently taking albuterol in the morning to open airways prior to taking his controller medication Still symptomatic and needs to gain control of his asthma Watch
.........................................................................................................................................................................................................................
Previously on ICS/LABA* Combination Therapy Nancy, Age 51 History Diagnosed with moderate persistent asthma History of not adhering to controller therapy Treatment Stopped taking ICS/LABA therapy and is now experiencing symptoms again Watch	Previously on ICS/LABA* Combination Therapy Barbara, Age 45 History Previously prescribed a combination maintenance medication for asthma, and stopped taking it Presented with difficulty breathing, a symptom indicative of uncontrolled asthma Treatment Prescribed SYMBICORT 160/4.5 mcg, 2 inhalations twice daily Watch

*Inhaled corticosteroid/long-acting beta2-agonist.

SYMBICORT is indicated for the long-term maintenance treatment of asthma in patients 12 years and older. SYMBICORT is NOT indicated for the relief of acute broncospasm and does not replace fast-acting inhalers. SYMBICORT is not indicated in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled short-acting beta₂-agonists.

Important Safety Information, including boxed WARNING

WARNING: Long-acting beta₂-adrenergic agonists may increase the risk of asthma-related death. SYMBICORT should only be used for patients with asthma not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled US study that compared the safety of another long-acting beta₂-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta₂-adrenergic agonist), one of the active ingredients in SYMBICORT (see WARNINGS in full Prescribing Information)
SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids
Patients who are receiving SYMBICORT should not use additional formoterol or other long-acting inhaled beta₂-agonists for any reason
Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. SYMBICORT, like all products containing sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
Long-term use of orally inhaled corticosteroids, such as budesonide, a component of SYMBICORT, may affect normal bone metabolism resulting in a loss of bone mineral density
Glaucoma, increased intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteroids, including budesonide, a component of SYMBICORT
SYMBICORT should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents
The most common adverse events ≥5% reported in clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, and stomach discomfort

Indications

SYMBICORT is indicated for the long-term maintenance treatment of asthma in patients 12 years and older
SYMBICORT is NOT indicated for the relief of acute bronchospasm and should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma
SYMBICORT is not indicated in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled short-acting beta₂-agonists

Please see full Prescribing Information, including boxed WARNING.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

This product information is intended for US health care professionals only.

SYMBICORT is a registered trademark of the AstraZeneca group of companies.

Legal Links: Legal Statement | Privacy Policy

Utilities: Site Map | Contact Us | Full Prescribing Information | US Corporate Site

Important Pages: Efficacy | Safety Profile | Dosing | References